GlaxoSmithKline
- 23andMe
- Abbvie
- AdnaGen
- Agilent Technologies
- Alexion Pharmaceuticals
- Amgen
- Astellas
- AstraZeneca
- Audentes Therapeutics
- Berkeley Lights
- Bio-Rad Laboratories
- Biogen
- Cancer Genetics
- Catalent
- Charles RIver Laboratories
- Dana-Farber Cancer Institute
- deCODE genetics
- Dicerna
- Dimension Therapeutics
- Exact Sciences
- Foundation Medicine
- GE Healthcare
- GeneInsight
- Gilead Sciences
- GlaxoSmithKline
- Halozyme Therapeutics
- Hitachi High-Technologies
- Horizon Discovery Group
- Human Longevity
- Illumina
- Jackson Laboratory
- Janssen Biotech
- LabCorp
- Maravai LifeSciences
- MD Anderson
- MDxHealth
- MedImmune
- Memorial Sloan Kettering Cancer Center
- Merck & Co
- Merck KGaA
- NanoString Technologies
- Novartis
- Pathology
- PerkinElmer
- PersonalizeDx
- Qiagen
- RayBiotech
- Roche
- Sanofi
- shire
- Sigma-Aldrich
- Synthego
- Takeda
- Thermo Fisher Scientific
- UCB Biosciences
![GlaxoSmithKline (GSK) has made a $300 million equity investment in 23andMe under a collaboration designed to accelerate development of new therapies for both companies by using genetic data to identify new drug targets. [Source: © fotoliaxrender/Fotolia]](https://www.genengnews.com/wp-content/uploads/2018/08/Aug5_2014_56448122_DNAblue_NovelDiagnosticGenomic12114111424-324x160.jpg "GSK Invests $300M in 23andMe as Companies Collaborate on Drug Development")
